Peptide record

TPDB91972

CA-MA-P CA-MA2 Antibacterial Anticancer Antifungal Antiparasitic Toxicity modified_plain modified
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB91972
CA-MA-P CA-MA2
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF
modified_plain
Yes
A 18-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
KWKLFKKIPKFLHSAKKF-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
18 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antibacterial Activity
Ceropin A Ceropin-Magainin hybrid peptides Activity
Evidence Records 7 records
Evidence 1 Activity

Activity

IC50
IC50=20 µM
Anticancer
20 µM

Target

Breast Cancer
MDA-MB-361
Breast

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2001

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=20 µM
Anticancer
20 µM

Target

Blood Cancer
Jurkat
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2001
Evidence 3 Activity

Activity

IC50
IC50=25 µM
Anticancer
25 µM

Target

Leukemia Cancer
K-562
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2001
Evidence 4 Activity

Activity

IC50
IC50=35.1 µM
Anticancer
35.1 µM

Target

Leukemia Cancer
K-562
Blood

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2000
Evidence 5 Activity

Activity

IC50
IC50=25 µM
Anticancer
25 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2000
Evidence 6 Activity

Activity

IC50
IC50=20 µM
Anticancer
20 µM

Target

Blood Cancer
Jurkat
Blood

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2000
Evidence 7 Activity

Activity

IC50
IC50=28 µM
Anticancer
28 µM

Target

Breast Cancer
MDA-MB-361
Breast

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2000